Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Summary

The purpose of this phase I study is to evaluate the safety and feasibility of SX-682 in combination with Nivolumab in patients with metastatic adenocarcinoma who have completed at least 16 weeks of first line chemotherapy treatment without evidence of disease progression.

General Information

NCT#: NCT04477343
Study ID: UGIP20027
Trial Phase: Phase I

Trial Sponsor: University of Rochester
Therapies Used in This Trial: Nivolumab, SX-682

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search